Schizophrenia and Schizoaffective Disorders

Schizophrenia and schizoaffective disorders are severe mental conditions characterized by hallucinations, delusions, and mood disturbances. The Journal of Clinical Psychiatry offers a deep dive into these disorders, emphasizing their diagnosis, management, and underlying causes. Our expert editors ensure content is both clinically relevant and actionable, aiding psychiatrists in offering effective and compassionate care.

Page 24

Recently published articles about Schizophrenia/Schizoaffective Disorders

Article

Antipsychotic Use and Cardiovascular Outcomes

April 11, 2017

Does your patient who is at high risk of cardiovascular disease need antipsychotic treatment? Read this article for insight on which antipsychotic medications have the lowest incidence of major...

Alejandro G. Szmulewicz , Federico Angriman , Felipe E. Pedroso , et al

Original Research

Metabolic Risk in Psychosis

April 11, 2017

Metabolic disorders are common in people with psychotic disorders, but treatment of metabolic risk factors in these patients is anything but universal. Discover how often treatment of metabolic disorders...

Jojanneke Bruins , Gerdina H. M. Pijnenborg , Edwin R. van den Heuvel , et al

Letter to the Editor

Psychotic Exacerbation Following Subcutaneous Leuprolide

April 6, 2017

Could leuprolide therapy cause a worsening of psychosis after an extended period of psychiatric stability? Here, read about a man with prior history of paranoid schizophrenia who experienced an...

Brian G. Mitchell , Ashley L. Adams , Poonam K. Thandi

Original Research

Antipsychotic Changes Affecting Tardive Dyskinesia and Parkinsonism

March 29, 2017

Can switching antipsychotic type or changing the dose reduce the symptoms of parkinsonism and tardive dyskinesia? Review the drug effects with changes in high and low dopamine-2 affinity in...

Charlotte L. Mentzel , P. Roberto Bakker , Jim van Os , et al

Original Research

Aripiprazole to Treat Bipolar Disorder

March 29, 2017

Read a randomized control trial evaluating the efficacy and safety of once-monthly long-acting injectable antipsychotic aripiprazole.

Joseph R. Calabrese , Raymond Sanchez , Na Jin , et al

ASCP Corner

Duration and Relevance of Untreated Psychiatric Disorders, 1: Psychotic Disorders

March 29, 2017

This month's ASCP Corner discusses the significant problem of untreated psychosis. The authors review the factors that contribute to a longer time to treatment, the impact of untreated psychosis,...

Jose M. Rubio , Christoph U. Correll